Bisphosphonate mechanism of action.
The nitrogen-containing bisphosphonates (N-BPs), alendronate and risedronate, are the only pharmacologic agents shown to prevent spine and nonvertebral fractures associated with postmenopausal and glucocorticoid-induced osteoporosis. At the tissue level, this is achieved through osteoclast inhibition, which leads to reduced bone turnover, increased bone mass, and improved mineralization. The molecular targets of bisphosphonates (BPs) have recently been identified. This review will discuss the mechanism of action of BPs, focusing on alendronate and risedronate, which are the two agents most widely studied. They act on the cholesterol biosynthesis pathway enzyme, farnesyl diphosphate synthase. By inhibiting this enzyme in the osteoclast, they interfere with geranylgeranylation (attachment of the lipid to regulatory proteins), which causes osteoclast inactivation. This mechanism is responsible for N-BP suppression of osteoclastic bone resorption and reduction of bone turnover, which leads to fracture prevention.
Reszka
Alfred A
AA
Department of Bone Biology and Osteoporosis Research, Merck Research Laboratories, West Point, PA 19486, USA.
Rodan
Gideon A
GA
D017209:Apoptosis; D001862:Bone Resorption / Q000378:metabolism*; D004164:Diphosphonates / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D008798:Mevalonic Acid / Q000037:antagonists & inhibitors; D010010:Osteoclasts / Q000187:drug effects* / Q000378:metabolism* / Q000502:physiology; D010024:Osteoporosis / Q000378:metabolism
D004164:Diphosphonates; D008798:Mevalonic Acid